Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

FCSC / Fibrocell Science Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 FIBROCELL SCIENCE INC COMMON STOCK Cusip #315721308 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #315721308 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #315721308 Item 1: Reporting Person - Abigail P.

FCSC / Fibrocell Science Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 2 FIBROCELL SCIENCE INC COMMON STOCK Cusip #315721308 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #315721308 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #315721308 Item 1: Reporting Person - Abigail P.

FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-02-12 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 8-K ______________________________________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2018 __________________________________________________

Stocks To Watch: Digging For Gems In The Shakeout

2018-02-10 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (1619-20)

Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble

2018-02-06 seekingalpha
Today we will discuss AMAG Pharmaceuticals (AMAG), which as expected got a nod from the FDA for expanded use of Feraheme (ferumoxytol injection) for all eligible adult patients with iron deficiency anemia (IDA) who are intolerant of or have not responded adequately to oral iron therapy. (335-5)

FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-02-05 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 8-K ______________________________________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2018 __________________________________________________

Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring

2018-02-01 seekingalpha
Market update: Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader market, which is up more than 6% this month. A more important driver has been solid deal-making activity, which is always a good indicator for market sentiment. (224-5)

What's in Store for Cardinal Health (CAH) in Q2 Earnings?

2018-01-30 zacks
Cardinal Health (CAH - Free Report) is set to report second-quarter fiscal 2018 results on Feb 8, before the closing bell. The company’s innovative product line, strategic buyouts, joint ventures and supply agreements indicate significant long-term opportunities. (54-0)

FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-01-30 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 8-K ______________________________________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 ___________________________________________________

Can Molecular Diagnostics Arm Up Hologic (HOLX) Q1 Earnings?

2018-01-29 zacks
Hologic, Inc. (HOLX - Free Report) is slated to report first-quarter fiscal 2018 financial results on Feb 8 after the closing bell. Last quarter, the company delivered a positive earnings surprise of 2.04%. Notably, Hologic’s earnings surpassed the Zacks Consensus Estimate in all the past four quarters with an average beat of 3.69%. (60-0)

Will Higher System Sales Drive Cerner's (CERN) Q4 Earnings?

2018-01-29 zacks
Cerner Corporation (CERN - Free Report) is set to report fourth-quarter fiscal 2017 results on Feb 6, after market closes. In the previous quarter, the company reported earnings of 61 cents per share, missing the Zacks Consensus Estimate by a penny. However, earnings rose 3.4% on a year-over-year basis. (60-0)

FCSC / Fibrocell Science Inc. 8-K (Current Report)

2018-01-26 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 8-K ______________________________________________________________________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 ___________________________________________________

Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

2018-01-23 zacks
Stryker Corporation’s (SYK - Free Report) fourth-quarter 2017 results are scheduled for release on Jan 30, 2018, after the market closes. In the said quarter, the company is expected to witness year-over-year revenue growth in all other business segments apart from Orthopedics, Medsurg and Neurotechnology and Spine. (85-0)

FCSC / Fibrocell Science Inc. ER

2018-01-08 sec.gov
November 13, 2017 John M. Maslowski President and Chief Executive Officer Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 Fibrocell Science, Inc. Registration Statement on Form S-1 Filed November 6, 2017 File No. 333-221375 Re: Dear Mr. Maslowski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

FCSC / Fibrocell Science Inc. ESP

2018-01-08 sec.gov
  Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341   December 5, 2017   VIA EDGAR   U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549   Attn:                                                                    Chris Edwards   Re:                             Fibrocell Science, Inc. Registration Statement on Form S-1(File No.


CUSIP: 315721209